Skip to Content
Center for International Blood and Marrow Transplant Research

MM23-01a

Main Content

Standard of Care Idecabtagene Vicleucel (Ide-cel) for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

Study #: MM23-01a

Study Status: Published

Presentation(s)

2023, ASH (Oral)

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.

Citation

Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman CL, Afrough A, Anderson LD Jr., Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau H, Mirza AS, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini MC.

Blood. 2025, Jul 10: 146(2): 146(2):167-177. doi: 10.1182/blood.2024026216. Epub 2025, Apr 08. PMCID:.

PubMed

PMID: 40198886

Abstract